Compare ABLV & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABLV | VERU |
|---|---|---|
| Founded | 2015 | 1971 |
| Country | China | United States |
| Employees | 89 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 36.8M |
| IPO Year | N/A | 1996 |
| Metric | ABLV | VERU |
|---|---|---|
| Price | $0.65 | $2.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 2.7K | ★ 45.1K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.59 | $0.36 |
| 52 Week High | $1.77 | $4.59 |
| Indicator | ABLV | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 58.77 |
| Support Level | $0.60 | $2.13 |
| Resistance Level | $0.73 | $2.70 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 15.46 | 90.43 |
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.